INMUNE BIO INC. Research and Development Expense
INMUNE BIO INC. (INMB) reported Research and Development Expense of $3.64 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-05-07
- INMUNE BIO INC. research and development expense for the quarter ending 2026-03-31 was $3.64M, a 52.34% decline year-over-year.
- INMUNE BIO INC. research and development expense for the quarter ending 2025-12-31 was $2.33M, a 68.33% decline year-over-year.
- INMUNE BIO INC. research and development expense for the quarter ending 2025-09-30 was $4.89M, a 51.46% decline year-over-year.
- INMUNE BIO INC. research and development expense for the quarter ending 2025-06-30 was $5.80M, a 17.71% decline year-over-year.
- INMUNE BIO INC. research and development expense for fiscal 2025 was $20.66M, a 37.71% decline from fiscal 2024.
- INMUNE BIO INC. research and development expense for fiscal 2024 was $33.17M, a 63.60% increase from fiscal 2023.
- INMUNE BIO INC. research and development expense for fiscal 2023 was $20.27M, a 18.78% increase from fiscal 2022.
- INMUNE BIO INC. research and development expense for fiscal 2022 was $17.07M, a 16.92% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $3.64M 10-Q · filed 2026-05-07 | $5.97M derived: sum of 2 quarters · filed 2026-05-07 | $10.86M derived: sum of 3 quarters · filed 2026-05-07 | $16.66M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2025-12-31 | $2.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $7.22M derived: sum of 2 quarters · filed 2026-03-30 | $13.02M derived: sum of 3 quarters · filed 2026-03-30 | $20.66M 10-K · filed 2026-03-30 | ||||
| 2025-09-30 | $4.89M 10-Q · filed 2025-10-30 | $10.69M derived: sum of 2 quarters · filed 2025-10-30 | $18.33M 10-Q · filed 2025-10-30 | $25.68M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2025-06-30 | $5.80M 10-Q · filed 2025-08-07 | $13.44M 10-Q · filed 2025-08-07 | $20.80M derived: sum of 3 quarters · filed 2026-05-07 | $30.86M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2025-03-31 | $7.64M 10-Q · filed 2026-05-07 | $14.99M derived: sum of 2 quarters · filed 2026-05-07 | $25.06M derived: sum of 3 quarters · filed 2026-05-07 | $32.11M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $7.35M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $17.42M derived: sum of 2 quarters · filed 2026-03-30 | $24.47M derived: sum of 3 quarters · filed 2026-03-30 | $33.17M 10-K · filed 2026-03-30 | ||||
| 2024-09-30 | $10.07M 10-Q · filed 2025-10-30 | $17.12M derived: sum of 2 quarters · filed 2025-10-30 | $25.81M 10-Q · filed 2025-10-30 | $31.82M derived: sum of 4 quarters · filed 2025-10-30 | ||||
| 2024-06-30 | $7.05M 10-Q · filed 2025-08-07 | $15.75M 10-Q · filed 2025-08-07 | $21.75M derived: sum of 3 quarters · filed 2025-08-07 | $27.74M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | $8.69M 10-Q · filed 2025-05-08 | $14.70M derived: sum of 2 quarters · filed 2025-05-08 | $20.68M derived: sum of 3 quarters · filed 2025-05-08 | $24.83M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | $6.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $11.99M derived: sum of 2 quarters · filed 2025-03-27 | $16.14M derived: sum of 3 quarters · filed 2025-03-27 | $20.27M 10-K · filed 2025-03-27 | ||||
| 2023-09-30 | $5.99M 10-Q · filed 2024-10-31 | $10.13M derived: sum of 2 quarters · filed 2024-10-31 | $14.27M 10-Q · filed 2024-10-31 | $17.68M derived: sum of 4 quarters · filed 2024-10-31 | ||||
| 2023-06-30 | $4.15M 10-Q · filed 2024-08-01 | $8.28M 10-Q · filed 2024-08-01 | $11.69M derived: sum of 3 quarters · filed 2024-08-01 | $16.85M derived: sum of 4 quarters · filed 2024-08-01 | ||||
| 2023-03-31 | $4.13M 10-Q · filed 2024-05-09 | $7.54M derived: sum of 2 quarters · filed 2024-05-09 | $12.70M derived: sum of 3 quarters · filed 2024-05-09 | $16.89M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | $3.41M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $8.57M derived: sum of 2 quarters · filed 2024-03-28 | $12.76M derived: sum of 3 quarters · filed 2024-03-28 | $17.07M 10-K · filed 2024-03-28 | ||||
| 2022-09-30 | $5.16M 10-Q · filed 2023-11-01 | $9.35M derived: sum of 2 quarters · filed 2023-11-01 | $13.66M 10-Q · filed 2023-11-01 | $20.73M derived: sum of 4 quarters · filed 2023-11-01 | ||||
| 2022-06-30 | $4.19M 10-Q · filed 2023-08-07 | $8.50M 10-Q · filed 2023-08-07 | $15.57M derived: sum of 3 quarters · filed 2023-08-07 | $22.09M derived: sum of 4 quarters · filed 2023-08-07 | ||||
| 2022-03-31 | $4.31M 10-Q · filed 2023-05-03 | $11.38M derived: sum of 2 quarters · filed 2023-05-03 | $17.90M derived: sum of 3 quarters · filed 2023-05-03 | $22.36M derived: sum of 4 quarters · filed 2023-05-03 | ||||
| 2021-12-31 | $7.07M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $13.59M derived: sum of 2 quarters · filed 2023-03-02 | $18.05M derived: sum of 3 quarters · filed 2023-03-02 | $20.54M 10-K · filed 2023-03-02 | ||||
| 2021-09-30 | $6.52M 10-Q · filed 2022-11-02 | $10.98M derived: sum of 2 quarters · filed 2022-11-02 | $13.47M 10-Q · filed 2022-11-02 | $15.33M derived: sum of 4 quarters · filed 2022-11-02 | ||||
| 2021-06-30 | $4.46M 10-Q · filed 2022-08-03 | $6.96M 10-Q · filed 2022-08-03 | $8.81M derived: sum of 3 quarters · filed 2022-08-03 | $11.18M derived: sum of 4 quarters · filed 2022-08-03 | ||||
| 2021-03-31 | $2.49M 10-Q · filed 2022-05-05 | $4.35M derived: sum of 2 quarters · filed 2022-05-05 | $6.71M derived: sum of 3 quarters · filed 2022-05-05 | $7.62M derived: sum of 4 quarters · filed 2022-05-05 | ||||
| 2020-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $4.22M derived: sum of 2 quarters · filed 2022-03-03 | $5.13M derived: sum of 3 quarters · filed 2022-03-03 | $5.92M 10-K · filed 2022-03-03 | $5.92M 10-K · filed 2021-03-04 | |||
| 2020-09-30 | $2.36M 10-Q · filed 2021-11-03 | $2.36M 10-Q · filed 2020-11-05 | $3.27M derived: sum of 2 quarters · filed 2021-11-03 | $4.06M 10-Q · filed 2021-11-03 | $4.06M 10-Q · filed 2020-11-05 | $4.93M derived: sum of 4 quarters · filed 2021-11-03 | ||
| 2020-06-30 | $903.00K 10-Q · filed 2021-08-04 | $903.04K 10-Q · filed 2020-08-05 | $1.70M 10-Q · filed 2021-08-04 | $1.70M 10-Q · filed 2020-08-05 | $2.56M derived: sum of 3 quarters · filed 2021-08-04 | $3.73M derived: sum of 4 quarters · filed 2021-08-04 | ||
| 2020-03-31 | $793.00K 10-Q · filed 2021-05-05 | $792.79K 10-Q · filed 2020-05-14 | $1.66M derived: sum of 2 quarters · filed 2021-05-05 | $2.83M derived: sum of 3 quarters · filed 2021-05-05 | $3.46M derived: sum of 4 quarters · filed 2021-05-05 | |||
| 2019-12-31 | $866.55K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $2.03M derived: sum of 2 quarters · filed 2021-03-04 | $2.67M derived: sum of 3 quarters · filed 2021-03-04 | $3.28M 10-K · filed 2021-03-04 | ||||
| 2019-09-30 | $1.17M 10-Q · filed 2020-11-05 | $1.80M derived: sum of 2 quarters · filed 2020-11-05 | $2.42M 10-Q · filed 2020-11-05 | $3.41M derived: sum of 4 quarters · filed 2020-11-05 | ||||
| 2019-06-30 | $634.70K 10-Q · filed 2020-08-05 | $293.81K 10-Q · filed 2019-08-09 | $1.25M 10-Q · filed 2020-08-05 | $395.40K 10-Q · filed 2019-08-09 | $2.24M derived: sum of 3 quarters · filed 2020-08-05 | $2.89M derived: sum of 4 quarters · filed 2020-08-05 | ||
| 2019-03-31 | $612.71K 10-Q · filed 2020-05-14 | $101.59K 10-Q · filed 2019-05-15 | $1.60M derived: sum of 2 quarters · filed 2020-05-14 | $2.26M derived: sum of 3 quarters · filed 2020-05-14 | $2.55M derived: sum of 4 quarters · filed 2020-05-14 | |||
| 2018-12-31 | $992.20K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-11 | $1.65M derived: sum of 2 quarters · filed 2020-03-11 | $1.93M derived: sum of 3 quarters · filed 2020-03-11 | $3.35M 10-K · filed 2020-03-11 | $1.11M 10-K · filed 2019-03-29 | |||
| 2018-09-30 | $654.69K 10-Q · filed 2019-11-08 | $942.01K derived: sum of 2 quarters · filed 2019-11-08 | $2.36M 10-Q · filed 2019-11-08 | |||||
| 2018-06-30 | $287.32K 10-Q · filed 2019-08-09 | $391.33K 10-Q · filed 2019-08-09 | ||||||
| 2018-03-31 | $104.01K 10-Q · filed 2019-05-15 | |||||||
| 2017-12-31 | $435.36K 10-K · filed 2019-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B |